Perceptive Advisors LLC recently announced the acquisition of new stake in VBI Vaccines Inc. (NASDAQ:VBIV). The institutional investor has increased its shareholding in the Healthcare company by 19.78% to 55.04 million shares with purchase of 9.09 million shares. This fresh investment now brings its stake to 23.86% valued currently at $224.02 million. In addition, BlackRock Fund Advisors raised its holdings by 1.14 million to 11.92 million shares. And The Vanguard Group, Inc. has lifted its position by 97.18% or 2.78 million shares – to 5.64 million shares.

With over 12.43 million VBI Vaccines Inc. (VBIV) shares trading Monday and a closing price of $4.26 on the day, the dollar volume was approximately $52.97 million. The shares have shown a positive weekly performance of 33.75% and its price on 08/31/20 gained nearly 6.77%. Currently, there are 231.20M common shares owned by the public and among those 150.88M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for VBIV have a consensus price objective of $6.75. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $3.00 should the stock experience a downside. Incidentally, analysts’ outlook for the VBI Vaccines Inc. stock is 1.50 for the next 12 months. But an upside of 52.67% will see the stock hit the forecast high price target while mean target price for the stock is $7.50.

Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 29,295,409 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in VBI Vaccines Inc. are iShares Russell 2000 ETF, Vanguard Extended Market Index Fu, and iShares Russell 2000 Growth ETF. iShares Russell 2000 ETF owns 3.53 million shares of the company’s stock, all valued at over $14.38 million. The company sold -0.17 million shares recently to bring their total holdings to about 1.53% of the shares outstanding. Vanguard Extended Market Index Fu sold 6729.0 shares to see its total holdings shrink to 3.25 million shares valued at over $13.24 million and representing 1.41% of the shares outstanding. iShares Russell 2000 Growth ETF sold 12952.0 shares to bring its total holdings to over 1.32 million shares at a value of $5.36 million. iShares Russell 2000 Growth ETF now owns shares totaling to 0.57% of the shares outstanding.

Shares of VBI Vaccines Inc. (NASDAQ: VBIV) opened at $4.004, up $0.01 from a prior closing price of $3.99. However, the script later closed the day at $4.26, up 6.77%. The company’s stock has a 5-day price change of 33.75% and 98.14% over the past three months. VBIV shares are trading 208.70% year to date (YTD), with the 12-month market performance up to 601.12% higher. It has a 12-month low price of $0.47 and touched a high of $6.93 over the same period. Currently, 12.43 million shares have been traded, compared to an average intraday trading volume of 15.65 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.65%, 7.88%, and 112.78% respectively.

Institutional ownership of VBI Vaccines Inc. (NASDAQ: VBIV) shares accounts for 44.45% of the company’s 231.20M shares outstanding. Mutual fund holders own 35.28%, while other institutional holders and individual stakeholders account for 8.99% and 30.56% respectively.

It has a market capitalization of $984.90M. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.24% over the week and 12.20% over the month.

Analysts forecast that VBI Vaccines Inc. (VBIV) will achieve an EPS of -$0.22 for the current quarter, -$0.21 for the next quarter and -$0.77 for 2019. The lowest estimate earnings-per-share for the quarter is -$0.22 while analysts give the company a high EPS estimate of -$0.22. Comparatively, EPS for the current quarter was -$0.24 a year ago. Earnings per share for the fiscal year are expected to decrease by 0.00%, and 12.50% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate VBI Vaccines Inc. (VBIV) as a “Strong Buy” at a consensus score of 1.50. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the VBIV, a number of firms have released research notes about the stock. Raymond James stated their Strong Buy rating for the stock in a research note on August 27, 2020, with the firm’s price target at $8-$9. Oppenheimer coverage for the VBI Vaccines Inc. (VBIV) stock in a research note released on January 16, 2019 offered a Outperform rating with a price target of $9. Canaccord Genuity was of a view on November 01, 2017 that the stock is Buy, while Laidlaw gave the stock Buy rating on October 10, 2016, issuing a price target of $6. Ladenburg Thalmann on their part issued Buy rating on July 26, 2016.